Showing results (1331-1340 of 3,470) with videos related to

Sort By:
Pageof 347
Herz|February 1, 1994
Potential and limitations of Tc-99m sestamibi scintigraphy for the diagnosis of myocardial viabilityJ H Cornel, M Arnese, T Forster, et al.
Expert Opinion on Pharmacotherapy|January 13, 2021
Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?Tanja Fens, Guiling Zhou, Maarten J Postma, et al.
Frontiers in Plant Science|April 3, 2023
Plant root plasticity during drought and recovery: What do we know and where to go?Congcong Zheng, Helena Bochmann, Zhaogang Liu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 2, 2008
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission modelBeate Sander, Azhar Nizam, Louis P Garrison, et al.
Thorax|November 1, 1994
Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study GroupH A Kerstjens, P L Brand, P M de Jong, et al.
The Annals of Otology, Rhinology, and Laryngology|December 5, 2023
Transnasal Humidified Rapid Insufflation Ventilatory Exchange in Endoscopic Esophageal SurgeryZao M Yang, Tuan-Hsing Loh, Justin Ross, et al.
BMC Health Services Research|November 1, 2019
Diabetes distress in Indonesian patients with type 2 diabetes: a comparison between primary and tertiary careBustanul Arifin, Antoinette D I van Asselt, Didik Setiawan, et al.
European Journal of Neurology|January 26, 2016
Association between eye position on brain scan and hospital mortality in acute intracerebral hemorrhageK J M Frusch, R Houben, F H B M Schreuder, et al.
Plos One|August 6, 2014
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the NetherlandsJelena Stevanović, Marjolein Pompen, Hoa H Le, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 29, 2017
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillationMaartje S Jacobs, Lisa A de Jong, Maarten J Postma, et al.
Pageof 347